| Jean Marie Holden, MSN APN FNP-BC | |
|
8 W 4th St, Barnegat Light, NJ 08006-1439 | |
| (609) 226-8532 | |
| Not Available |
| Full Name | Jean Marie Holden |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 9 Years |
| Location | 8 W 4th St, Barnegat Light, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538540778 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 26NJ00572800 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Summit Medical Group Pa | 5395642276 | 1253 |
News Archive
Drugs that are used in the clinic to treat some forms of breast and kidney cancer and that work by inhibiting the signaling molecule mTORC1 might have utility in treating some of the more than 15 percent of human cancers driven by alterations in the Myc gene, according to data from a preclinical study published in Cancer Discovery, a journal of the American Association for Cancer Research.
Reflectance Medical, a commercial-stage company focused on the development of physiologic sensors to non-invasively and continuously assess patient metabolic status, announced today that it has received FDA 510(k) clearance for its initial product, the CareGuide Oximeter.
Spheris, a leading global provider of clinical documentation technology and services, today announced that it has entered into an agreement under which MedQuist Inc. and CBay Inc., portfolio companies of CBaySystems Holdings Ltd. and leading providers of medical transcription software and services, have agreed to purchase substantially all of Spheris' assets pursuant to a transaction that is to be implemented under Section 363 of the United States Bankruptcy Code.
A new California law set to take effect in January 2007 "provides a glimpse of the type of government price controls the drug industry fears," the Boston Globe reports.
› Verified 3 days ago
| Entity Name | Summit Medical Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942254347 PECOS PAC ID: 5395642276 Enrollment ID: O20031218000011 |
News Archive
Drugs that are used in the clinic to treat some forms of breast and kidney cancer and that work by inhibiting the signaling molecule mTORC1 might have utility in treating some of the more than 15 percent of human cancers driven by alterations in the Myc gene, according to data from a preclinical study published in Cancer Discovery, a journal of the American Association for Cancer Research.
Reflectance Medical, a commercial-stage company focused on the development of physiologic sensors to non-invasively and continuously assess patient metabolic status, announced today that it has received FDA 510(k) clearance for its initial product, the CareGuide Oximeter.
Spheris, a leading global provider of clinical documentation technology and services, today announced that it has entered into an agreement under which MedQuist Inc. and CBay Inc., portfolio companies of CBaySystems Holdings Ltd. and leading providers of medical transcription software and services, have agreed to purchase substantially all of Spheris' assets pursuant to a transaction that is to be implemented under Section 363 of the United States Bankruptcy Code.
A new California law set to take effect in January 2007 "provides a glimpse of the type of government price controls the drug industry fears," the Boston Globe reports.
› Verified 3 days ago
| Entity Name | Barron Emergency Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790736940 PECOS PAC ID: 8820083785 Enrollment ID: O20040419001416 |
News Archive
Drugs that are used in the clinic to treat some forms of breast and kidney cancer and that work by inhibiting the signaling molecule mTORC1 might have utility in treating some of the more than 15 percent of human cancers driven by alterations in the Myc gene, according to data from a preclinical study published in Cancer Discovery, a journal of the American Association for Cancer Research.
Reflectance Medical, a commercial-stage company focused on the development of physiologic sensors to non-invasively and continuously assess patient metabolic status, announced today that it has received FDA 510(k) clearance for its initial product, the CareGuide Oximeter.
Spheris, a leading global provider of clinical documentation technology and services, today announced that it has entered into an agreement under which MedQuist Inc. and CBay Inc., portfolio companies of CBaySystems Holdings Ltd. and leading providers of medical transcription software and services, have agreed to purchase substantially all of Spheris' assets pursuant to a transaction that is to be implemented under Section 363 of the United States Bankruptcy Code.
A new California law set to take effect in January 2007 "provides a glimpse of the type of government price controls the drug industry fears," the Boston Globe reports.
› Verified 3 days ago
| Entity Name | The Urgent Care Group, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912177908 PECOS PAC ID: 9638196777 Enrollment ID: O20051028000273 |
News Archive
Drugs that are used in the clinic to treat some forms of breast and kidney cancer and that work by inhibiting the signaling molecule mTORC1 might have utility in treating some of the more than 15 percent of human cancers driven by alterations in the Myc gene, according to data from a preclinical study published in Cancer Discovery, a journal of the American Association for Cancer Research.
Reflectance Medical, a commercial-stage company focused on the development of physiologic sensors to non-invasively and continuously assess patient metabolic status, announced today that it has received FDA 510(k) clearance for its initial product, the CareGuide Oximeter.
Spheris, a leading global provider of clinical documentation technology and services, today announced that it has entered into an agreement under which MedQuist Inc. and CBay Inc., portfolio companies of CBaySystems Holdings Ltd. and leading providers of medical transcription software and services, have agreed to purchase substantially all of Spheris' assets pursuant to a transaction that is to be implemented under Section 363 of the United States Bankruptcy Code.
A new California law set to take effect in January 2007 "provides a glimpse of the type of government price controls the drug industry fears," the Boston Globe reports.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jean Marie Holden, MSN APN FNP-BC Po Box 223, 8 W 4th St, Barnegat Light, NJ 08006-0223 Ph: (609) 226-8532 | Jean Marie Holden, MSN APN FNP-BC 8 W 4th St, Barnegat Light, NJ 08006-1439 Ph: (609) 226-8532 |
News Archive
Drugs that are used in the clinic to treat some forms of breast and kidney cancer and that work by inhibiting the signaling molecule mTORC1 might have utility in treating some of the more than 15 percent of human cancers driven by alterations in the Myc gene, according to data from a preclinical study published in Cancer Discovery, a journal of the American Association for Cancer Research.
Reflectance Medical, a commercial-stage company focused on the development of physiologic sensors to non-invasively and continuously assess patient metabolic status, announced today that it has received FDA 510(k) clearance for its initial product, the CareGuide Oximeter.
Spheris, a leading global provider of clinical documentation technology and services, today announced that it has entered into an agreement under which MedQuist Inc. and CBay Inc., portfolio companies of CBaySystems Holdings Ltd. and leading providers of medical transcription software and services, have agreed to purchase substantially all of Spheris' assets pursuant to a transaction that is to be implemented under Section 363 of the United States Bankruptcy Code.
A new California law set to take effect in January 2007 "provides a glimpse of the type of government price controls the drug industry fears," the Boston Globe reports.
› Verified 3 days ago